Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach

被引:9
作者
Hass, Bastian [1 ]
Lungershausen, Juliane [1 ]
Hertel, Nadine [1 ]
Nautrup, Barbara Poulsen [2 ]
Kotowa, Wioletta [1 ]
Liedgens, Hiltrud [3 ]
机构
[1] IMS HEALTH GmbH & CO OHG, Hlth Econ & Outcomes Res, D-90402 Nurnberg, Germany
[2] EAH Consulting, Julich, Germany
[3] Grunenthal GmbH, Aachen, Germany
关键词
Buprenorphine; Chronic pain; Cost-effectiveness-analysis; Fractures; Opioids; TRANSDERMAL BUPRENORPHINE; NONCANCER PAIN; OSTEOPOROSIS; CANCER; FENTANYL; GERMAN; EUROPE; LIFE;
D O I
10.1007/s10198-008-0134-1
中图分类号
F [经济];
学科分类号
02 ;
摘要
Opioid analgesics are known to impact on the central nervous system (CNS). These CNS side effects, such as dizziness and confusion, have been shown to lead to an increased risk of falling with subsequent fractures in elderly patients being treated with opioids. The risk of experiencing fractures has been shown to be dependent on the substance administered. Therefore, a health economic model was developed to investigate the cost-effectiveness of the most commonly used strong opiods in Germany, focussing on opioid-related fractures. By means of a Markov model, the consequences of hip, spine and forearm fractures due to the prior administration of transdermal (TD) buprenorphine, TD fentanyl, oral oxycodone as well as oral morphine were assessed from the perspectives of the German statutory health insurance (SHI) and the German social security (GSS) system over a time horizon of 6 years. The most frequently prescribed strength/package-size combinations of these opioids were taken into consideration, including generics where available. The results of the present analysis predict that TD buprenorphine is dominant compared to TD fentanyl and oxycodone by showing better effects [life years gained/quality adjusted life years (QALY) gained] at lower cost. From the SHI perspective, the incremental cost-effectiveness ratio (ICER) compared to morphine is a,not sign 6,801.61 per life year gained, and a,not sign 7,766.11 per QALY gained. From the GSS perspective, the ICER is a,not sign 2,496.77 per life year gained and a,not sign 2,850.83 per QALY gained. The model is robust regarding probabilistic variations of all parameters in the sensitivity analyses. Focussing on fractures due to the prior administration of strong opioids, TD buprenorphine is less costly and more effective than TD fentanyl and oxycodone and represents a cost-effective treatment option versus morphine in patients with chronic pain from both the SHI and GSS perspective in Germany.
引用
收藏
页码:309 / 321
页数:13
相关论文
共 44 条
[1]  
AKESSON K, 2001, OSTEOPOROSIS FRACTUR
[2]  
[Anonymous], 2006, GUID EC EV HLTH TECH, V3rd
[3]  
[Anonymous], GUID METH TECHN APPR
[4]   Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: Lessons for inferring generalizability [J].
Barbieri, M ;
Drummond, M ;
Willke, R ;
Chancellor, J ;
Jolain, B ;
Towse, A .
VALUE IN HEALTH, 2005, 8 (01) :10-23
[5]  
*BAY ROT KREUZ WEI, 2006, RETT
[6]  
BOGER RH, 2007, ARZNEIVERORDNUNGS RE, P233
[7]   Hospitalised osteoporotic vertebral fractures in Spain:: Analysis of the national hospital discharge registry [J].
Bouza, C. ;
Lopez, T. ;
Palma, M. ;
Amate, J. M. .
OSTEOPOROSIS INTERNATIONAL, 2007, 18 (05) :649-657
[8]  
Brecht JG, 2003, INT J CLIN PHARM RES, V23, P93
[9]   Survey of chronic pain in Europe: Prevalence, impact on daily life, and treatment [J].
Breivik, H ;
Collett, B ;
Ventafridda, V ;
Cohen, R ;
Gallacher, D .
EUROPEAN JOURNAL OF PAIN, 2006, 10 (04) :287-333
[10]  
*BUND BILD FORSCH, 2001, CHRON SCHMERZ